Abstract:Drug-induced liver injury (DILI) encompasses a spectrum of clinical disease ranging from mild biochemical abnormalities to acute liver failure. The majority of adverse liver reactions are idiosyncratic, occurring in most instances 5-90 days after the causative medication was last taken. The diagnosis of DILI is clinical, based on history, probability of the suspect medication as a cause of liver injury and exclusion of other hepatic disease. DILI can be hepatocellular (predominant rise in alanine transaminase), cholestatic (predominant rise in alkaline phosphatase) or mixed liver injury. An elevated bilirubin level more than twice the upper limit of normal in patients with hepatocellular liver injury implies severe DILI, with a mortality of approximately 10% and with an incidence rate of 0.7-1.3 per 100,000. Although acute liver failure is rare, 13-17% of all acute liver failure cases are attributed to idiosyncratic drug reactions. Response to drug withdrawal may be delayed up to 1 year with cholestatic liver injury with occasional subsequent progressive cholestasis known as the vanishing bile duct syndrome. Overall, chronic disease may occur in up to 6% even if the offending drug is withdrawn. Antibiotics and NSAIDs are the most common cause of DILI. Statins rarely cause significant liver injury whereas antiretroviral therapy is associated with hepatotoxicity in 10% of treated patients. Multiple mechanisms of DILI have been implicated, including TNF-alpha-activated apoptosis, inhibition of mitochondrial function and neoantigen formation. Risk factors for DILI include age, sex and genetic polymorphisms of drug-metabolising enzymes such as cytochrome P450. In patients with human immunodeficiency virus, the presence of chronic viral hepatitis increases the risk of antiretroviral therapy hepatotoxicity. Over the next decade, the combination of accurate case ascertainment of DILI via clinical networks and the application of genomics and proteomics will hopefully lead to accurate prediction of risk of DILI, so that pharmacotherapy can be optimised with avoidance of adverse hepatic events.

Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems

The Liver Toxicity Knowledge Base (LKTB) and Drug-Induced Liver Injury (DILI) Classification for Assessment of Human Liver Injury

An Analysis of the Efficacy and Safety of Compound Glycyrrhizin Injections in the Treatment of Drug-Induced Liver Injury Using a Nationwide Database.

Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review

Idiosyncratic drug-induced liver injury: an overview

Clinical management of patients with drug-induced liver injury (DILI)

Drug-induced liver injury: a comprehensive review

Clinical features of drug-induced liver failure and related diagnosis and treatment strategies

Dissecting the molecular pathophysiology of drug-induced liver injury

Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review

Idiosyncratic drug-induced liver injury: an update on the 2007 overview

N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review

ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury

[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

[Research Progress on Laboratory Diagnosis of Drug-Induced Liver Injury].

[Promoting Translational Research on Drug-Induced Liver Injury].

Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry

Hospital Admissions for Drug-Induced Liver Injury: Clinical Features, Therapy, and Outcomes

Multidisciplinary Expert Consensus on Clinical Features and Prognosis of Drug-Induced Liver Injury

Prevention and treatment current situation of drug-induced liver Injury

Standardize the Diagnosis and Treatment of Drug-Induced Liver Injury, and Strengthen Clinical and Translational Research